Misplaced Pages

Vamicamide: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 06:16, 19 December 2024 editGraeme Bartlett (talk | contribs)Administrators249,639 edits added Category:Amides using HotCat← Previous edit Latest revision as of 03:14, 29 December 2024 edit undoInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,014 editsNo edit summary 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{Infobox drug {{Infobox drug
| drug_name = Vamicamide | drug_name = Vamicamide
| image = Vamicamide.svg | image = Vamicamide v2.svg
| width = 250px | width = 200px
| caption = | caption =


Line 24: Line 24:


<!-- Legal status --> <!-- Legal status -->
| legal_status = | legal_status = Investigational


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 58: Line 58:
| StdInChIKey = BWNLUIXQIHPUGO-RDTXWAMCSA-N | StdInChIKey = BWNLUIXQIHPUGO-RDTXWAMCSA-N
}} }}
'''Vamicamide''', also known as FK-176 or Urocut, is a ] (mAChR) antagonist that was developed by ] (now part of ]) for the treatment of ] and ].<ref name = "PatSnap"/> This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters,<ref name="Yamamoto_1995">{{cite journal | vauthors = Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M | title = Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency | journal = The Journal of Urology | volume = 154 | issue = 6 | pages = 2174–8 | date = December 1995 | pmid = 7500484 | doi = | url = }}</ref> vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the ] (NDA) phase in Japan.<ref name = "PatSnap">{{cite web | title = Vamicamide | url = https://synapse.patsnap.com/drug/eaf5bdd08c71489181d6c8f1bc01a636 | work = PatSnap }}</ref> '''Vamicamide''', also known as FK-176 or Urocut, is a ] (mAChR) ] that was developed by ] (now part of ]) for the treatment of ] and ].<ref name = "PatSnap"/> This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters,<ref name="Yamamoto_1995">{{cite journal | vauthors = Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M | title = Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency | journal = The Journal of Urology | volume = 154 | issue = 6 | pages = 2174–8 | date = December 1995 | pmid = 7500484 | doi = 10.1016/S0022-5347(01)66723-5| url = }}</ref> vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the ] (NDA) phase in Japan.<ref name = "PatSnap">{{cite web | title = Vamicamide | url = https://synapse.patsnap.com/drug/eaf5bdd08c71489181d6c8f1bc01a636 | work = PatSnap }}</ref>


== References == == References ==
Line 65: Line 65:
] ]
] ]
]
]
]

Latest revision as of 03:14, 29 December 2024

Pharmaceutical compound
Vamicamide
Clinical data
Other namesUrocut, FK-176
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (2R,4R)-4-(dimethylamino)-2-phenyl-2-pyridin-2-ylpentanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC18H23N3O
Molar mass297.402 g·mol
3D model (JSmol)
SMILES
  • C(C(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)N(C)C
InChI
  • InChI=1S/C18H23N3O/c1-14(21(2)3)13-18(17(19)22,15-9-5-4-6-10-15)16-11-7-8-12-20-16/h4-12,14H,13H2,1-3H3,(H2,19,22)/t14-,18-/m1/s1
  • Key:BWNLUIXQIHPUGO-RDTXWAMCSA-N

Vamicamide, also known as FK-176 or Urocut, is a muscarinic acetylcholine receptor (mAChR) antagonist that was developed by Fujisawa (now part of Astellas Pharma) for the treatment of urinary incontinence and overactive bladder. This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters, vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the New Drug Application (NDA) phase in Japan.

References

  1. ^ "Vamicamide". PatSnap.
  2. Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M (December 1995). "Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency". The Journal of Urology. 154 (6): 2174–8. doi:10.1016/S0022-5347(01)66723-5. PMID 7500484.
Categories: